title: Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is a highly aggressive cancer with few treatment options. Toll-like receptor 3 (TLR3) plays a key role in innate immunity and may affect the development of cancers. This study aimed to investigate whether TLR3 polymorphisms were associated with susceptibility to HCC. Two polymorphisms in the TLR3 gene, -976T/A and +1234C/T, were tested by polymerase chain reaction-restriction fragment length polymorphism in 466 HCC patients and 482 healthy controls. Results showed that the prevalence of +1234CT genotype and +1234TT genotype were significantly increased in the HCC cases than in controls (odds ratio [OR] =1.51; 95 % confidence interval [CI]; 1.22-1.93; p=0.004 and OR=3.19; 95 % CI, 1.82-5.39; p=1.99 × 10(-5), respectively). The -976T/A polymorphism did not reveal any differences between cases and controls. When analyzing the TLR3 +1234C/T polymorphism with different clinical parameters in HCC patients, the cases who were hepatitis B virus (HBV) carriers had higher number of +1234CT genotype and +1234T allele than those without HBV infection (p=0.032 and p=0.043). These data indicate that TLR3 +1234C/T polymorphism could be a novel risk factor for HCC, especially the HBV-related HCC.
authors: Department of ICU, General Hospital of Beijing Military Command, Beijing, 100700, China.
authors: Guanggang
authors: G
authors: Li
authors: Zhendong
authors: Z
authors: Zheng
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000473:pathology / Q000821:virology; D016022:Case-Control Studies; D004247:DNA / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006509:Hepatitis B / Q000235:genetics* / Q000473:pathology / Q000821:virology; D006515:Hepatitis B virus / Q000472:pathogenicity*; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D051196:Toll-Like Receptor 3 / Q000235:genetics*
chemical_list: C495344:TLR3 protein, human; D051196:Toll-Like Receptor 3; D004247:DNA
references: J Exp Med. 1998 Jul 20;188(2):341-50
references: 9670046
references: Annu Rev Immunol. 2003;21:335-76
references: 12524386
references: Hepatology. 2008 Jul;48(1):322-35
references: 18506843
references: Int J Oncol. 2008 Nov;33(5):929-36
references: 18949355
references: J Immunol. 2002 May 1;168(9):4531-7
references: 11970999
references: Annu Rev Immunol. 2006;24:353-89
references: 16551253
references: Cell. 2006 Feb 24;124(4):783-801
references: 16497588
references: J Immunol. 2012 Jan 15;188(2):818-23
references: 22174453
references: Vaccine. 2008 Mar 25;26(14):1731-6
references: 18325643
references: Int J Cancer. 2012 Feb 1;130(3):671-6
references: 21412764
references: Science. 2007 Jul 6;317(5834):121-4
references: 17615358
references: Am J Pathol. 2010 Dec;177(6):3192-201
references: 20971743
references: Int J Cancer. 2002 Oct 10;101(5):415-22
references: 12216068
references: Clin Microbiol Rev. 2008 Jan;21(1):13-25
references: 18202435
references: J Immunol. 2006 Apr 15;176(8):4894-901
references: 16585585
references: J Biol Chem. 2007 Jun 15;282(24):17696-705
references: 17434873
references: Oncol Rep. 2012 Feb;27(2):396-402
references: 22075935
references: Mol Biol Rep. 2012 Jul;39(7):7263-9
references: 22311043
references: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4565-74
references: 17671143
references: Cell Biol Int. 2011 Aug;35(8):803-10
references: 21418039
references: Cancer. 1994 Nov 15;74(10):2772-80
references: 7954236
references: Int Immunol. 2005 Jan;17(1):1-14
references: 15585605
references: Oncogene. 2006 Jun 26;25(27):3823-33
references: 16799624
references: Hepatology. 2007 Dec;46(6):1769-78
references: 17929296
references: J Antimicrob Chemother. 2012 Apr;67(4):789-801
references: 22258929
references: Curr Opin Immunol. 2003 Aug;15(4):396-401
references: 12900270